We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Low-Cost, Easy-to-Use Lab-on-Paper SARS-CoV-2 Diagnostic Test Provides Accurate Results within an Hour

By LabMedica International staff writers
Posted on 21 Jun 2021
Researchers have invented an easy-to-use, affordable lab-on-paper diagnostic technology for SARS-CoV-2, the virus that causes COVID-19 infection, that provides accurate results within an hour.

The device developed by researchers at University of Connecticut (Mansfield, CT, USA) uses a specialized kind of paper material to detect for two SARS-CoV-2 genes - the spike (S) and nucleoprotein (N) genes. More...
The clinical samples validated these genes as good candidates for diagnostic tests because they are highly conserved. This means they are so essential to the virus they are likely found in all variants. By testing two genes rather than one, the test is more accurate.

This point-of-care test can be performed by any health care professional, making it ideal for settings like community health centers. The simple, low-cost device provides a reliable result within an hour. Patients provide a sample from a nasal swap. Then the practitioner uses a commercially available kit to purify the nucleic acid in the sample. This removes any impurities that could interfere with the accuracy of the test. After about 15 minutes, the sample can be transferred to a device that uses CRISPR technology to detect the SARS-CoV-2 genes. CRISPR is a gene-editing technology that can alter an organism’s genome by targeting and cutting specific DNA or RNA segments.

As a diagnostic tool, CRISPR locates the genes of interest, in this case the S and N genes, and cut them. This cut produces an observable signal, which on the device is fluorescence filling in on the paper to indicate a positive result. In addition to the two SARS-CoV-2 genes, the device also tests for a “housekeeping” gene known as the RNase P (RP) gene. The presence of this gene lets the practitioner know they got a high-quality sample that will generate a reliable result. The device is on a cellulose-based paper membrane which is hydrophilic, meaning it can transport the liquid solution that contains the nucleic acid. This is a great advantage to practitioners as the test runs automatically after they load the sample. The paper is also formulated so that it does not interfere with the biochemical reactions that need to happen to select for the genes of interest. If there is interference, the test could produce a false signal. This technology can be applied for diagnosing other pathogens such as HIV, influenza viruses or high-risk HPV by modifying which genes it selects for.

“We took advantage of the high sensitivity and specificity of CRISPR technology,” said Changchun Liu, associate professor in the Department of Biomedical Engineering, who invented the diagnostic technology. “We want to continue to explore this technology and expand it for the detection of other pathogens.”

Related Links:
University of Connecticut


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.